Tafinlar 50 mg/1
dabrafenib · CAPSULE · Novartis Pharmaceuticals Corporation
Tafinlar (dabrafenib) is an oral prescription capsule used to treat certain types of cancer, particularly melanoma and other cancers with specific genetic mutations. It works by blocking proteins that help cancer cells grow and divide.
Key Facts
- Brand Name
- Tafinlar
- Generic Name
- dabrafenib
- NDC Code (Product)
0078-0682- Manufacturer
- Novartis Pharmaceuticals Corporation
- Strength
- 50 mg/1
- Dosage Form
- CAPSULE
- Route
- ORAL
- Marketing Status
- Application #
- NDA202806
- Marketing Start
- 04/12/2016
Recall History
No Recall HistorySide Effects Reported to FDA
FDA FAERS database · These are reported events, not confirmed side effects
Frequently Asked Questions
What is Tafinlar used for?
Tafinlar (dabrafenib) is an oral prescription capsule used to treat certain types of cancer, particularly melanoma and other cancers with specific genetic mutations. It works by blocking proteins that help cancer cells grow and divide.
Is Tafinlar a controlled substance?
Tafinlar is not classified as a controlled substance by the DEA.
What is the generic name for Tafinlar?
The generic name for Tafinlar is dabrafenib. There are no other listed brand versions of dabrafenib.
What is the NDC code for Tafinlar 50 mg/1?
The NDC (National Drug Code) for Tafinlar 50 mg/1 is 0078-0682, listed by Novartis Pharmaceuticals Corporation.
Other Tafinlar Dosages
Not medical advice. Always consult your doctor or pharmacist before making any medication decisions.
Data from openFDA · Public domain (CC0 1.0)